Bailey Timothy C, Da Silva Keith A, Lewis James F, Rodriguez-Capote Karina, Possmayer Fred, Veldhuizen Ruud A W
Department of Physiology and Pharmacology, Lawson Health Research Institute, University of Western Ontario, London, ON, Canada N6A 4V2.
J Appl Physiol (1985). 2004 May;96(5):1674-80. doi: 10.1152/japplphysiol.01143.2003. Epub 2003 Dec 29.
Pulmonary surfactant is a mixture of phospholipids ( approximately 90%) and surfactant-associated proteins (SPs) ( approximately 10%) that stabilize the lung by reducing the surface tension. One proposed mechanism by which surfactant is altered during acute lung injury is via direct oxidative damage to surfactant. In vitro studies have revealed that the surface activity of oxidized surfactant was impaired and that this effect could be overcome by adding SP-A. On the basis of this information, we hypothesized that animals receiving oxidized surfactant preparations would exhibit an inferior physiological and inflammatory response and that the addition of SP-A to the oxidized preparations would ameliorate this response. To test this hypothesis, mechanically ventilated, surfactant-deficient rats were administered either bovine lipid extract surfactant (BLES) or in vitro oxidized BLES of three doses: 10 mg/kg, 50 mg/kg, or 10 mg/kg + SP-A. When instilled with 10 mg/kg normal surfactant, the rats had a significantly superior arterial Po2 responses compared with the rats receiving oxidized surfactant. Interestingly, increasing the dose five times mitigated this physiological effect, and the addition of SP-A to the surfactant preparation had little impact on improving oxygenation. There were no differences in alveolar surfactant pools and the indexes of pulmonary inflammation between the 10 mg/kg dose groups, nor was there any differences observed between either of the groups supplemented with SP-A. However, there was significantly more surfactant and more inflammatory cytokines in the 50 mg/kg oxidized BLES group compared with the 50 mg/kg BLES group. We conclude that instillation of an in vitro oxidized surfactant causes an inferior physiological response in a surfactant-deficient rat.
肺表面活性物质是磷脂(约90%)和表面活性物质相关蛋白(SPs)(约10%)的混合物,可通过降低表面张力来稳定肺脏。急性肺损伤期间表面活性物质发生改变的一种推测机制是表面活性物质受到直接氧化损伤。体外研究表明,氧化后的表面活性物质的表面活性受损,而添加SP-A可克服这种影响。基于这些信息,我们推测,接受氧化表面活性物质制剂的动物会表现出较差的生理和炎症反应,而向氧化制剂中添加SP-A将改善这种反应。为了验证这一假设,对机械通气的表面活性物质缺乏的大鼠给予牛肺脂质提取物表面活性物质(BLES)或三种剂量的体外氧化BLES:10mg/kg、50mg/kg或10mg/kg + SP-A。当给予10mg/kg正常表面活性物质时,与接受氧化表面活性物质的大鼠相比,这些大鼠的动脉血氧分压反应明显更好。有趣的是,将剂量增加五倍可减轻这种生理效应,并且向表面活性物质制剂中添加SP-A对改善氧合作用影响不大。10mg/kg剂量组之间的肺泡表面活性物质池和肺部炎症指标没有差异,补充SP-A的任何一组之间也未观察到差异。然而,与50mg/kg BLES组相比,50mg/kg氧化BLES组中的表面活性物质和炎症细胞因子明显更多。我们得出结论,在表面活性物质缺乏的大鼠中滴注体外氧化的表面活性物质会导致较差的生理反应。